| April 1998 - June 1998# | |||
| Biotech Company** | Product | Pharma Partner | Type Arrangement/Geographic Area/ |
| (Country) | (Country) | Details (Date) | |
| Access | Aphthasol (amlexanox | Block Drug Co. | Access licensed marketing rights to prod- |
| Pharmaceuticals | oral paste 5% for treat- | (NASDAQ:BLOCA) | uct for all markets except U.S., Japan and |
| Inc. (OTC Bulletin | ing aphthous ulcers; | Israel; Access will share in international | |
| Board:AXCS) | FDA-approved) | product revenues and assume international | |
| responsibility for sublicensing, regulatory | |||
| approvals and new product development; | |||
| parties will share certain regulatory and | |||
| development costs (6/98) | |||
| Alza Corp. | Ditropan (oxybutynin | Procter & Gamble | Alza acquired Canadian marketing rights |
| chloride) for treating | Pharmaceuticals Canada | and also acquired right to use Ditropan | |
| urge urinary inconti- | (subsidiary of The | trademark in Canada with other Alza pro- | |
| nence (Alza submitted | Procter & Gamble | ducts; Hoechst Marion Roussel will man- | |
| NDA in 12/97 on an | Co.; NYSE:PG) and | ufacture and package product; Alza will | |
| OROS controlled- | Hoechst Marion Roussel | submit marketing application for Ditropan | |
| release formulation of | Inc. (subsidiary of | XL in Canada (4/98) | |
| product, Ditropan XL) | Hoechst AG; Germany) | ||
| American | Thrombus precursor | Shield Diagnostics Ltd. | Shield will distribute product in U.K. |
| Biogenetic Sciences | protein (TpP) diagnostic | (U.K.) | (4/98) |
| Inc. | kit; immunoassay that | ||
| measures soluble fibrin; | |||
| for diagnosing blood | |||
| clot formation | |||
| Anesta Corp. | Product line of oral | Laboratoire L. Lafon | Lafon has exclusive right to market, sell |
| transmucosal fentanyl | (France) | and distribute products in France (6/98) | |
| products, including | |||
| Actiq (for treating | |||
| breakthrough pain in | |||
| cancer patients) | |||
| Anika Therapeutics | Orthovisc (hyaluronic | Zimmer Inc. (subsid- | Expansion of 11/97 marketing agreement |
| Inc. (NASDAQ:ANIK) | acid) for treating osteo- | iary of Bristol-Myers | to include sales, marketing and distribution |
| arthritis of the knee | Squibb Co.; NYSE: | in Europe, Scandinavia and Latin America; | |
| (FDA accepted PMA | BMY) | Anika gets $3.5M in licensing fees, includ- | |
| for filing 2/98) | ing $1.5M up front (6/98) | ||
| Bio-Technology | BioLon (1% solution | Akorn Inc. | Akorn gets license to distribute and market |
| General Corp. | of sodium hyaluronate) | (NASDAQ:AKRN) | product in U.S. (4/98) |
| for use in ophthalmic | |||
| surgical procedures | |||
| (i.e., cataract removal) | |||
| Bio-Technology | Serono's line of | Serono Laboratories | Bio-Technology General will comarket |
| General Corp. | pediatric growth pro- | Inc. (member of the | products in U.S. and get share of revenues; |
| ducts: Saizen (recom- | Ares-Serono Group; | further details ND (5/98) | |
| binant human growth | Switzerland) | ||
| hormone for treating | |||
| growth hormone defic- | |||
| iency in children); | |||
| Geref (growth hormone | |||
| releasing hormone for | |||
| treating idiopathic | |||
| growth hormone | |||
| deficiency in children); | |||
| and Geref Diagnostic | |||
| (for diagnosing growth | |||
| disorders) | |||
| Biota Holdings Ltd. | Biota's AB FLU OIA | PanBio Pty Ltd. | PanBio will market and distribute product |
| (ASX:BTA; | (optical immunoassay; | (Australia) | in Australia; Biota retains worldwide mar- |
| Australia) | rapid point-of-care | keting rights outside Australia and U.S. | |
| diagnostic test for | (5/98) | ||
| influenza strains A and | |||
| B as well as variants) | |||
| Cellomics Inc.* | Integrated systems and | Carl Zeiss Jena GmbH | Exclusive worldwide comarketing, manu- |
| services for drug dis- | (Germany) | facturing and sales agreement on combined | |
| covery process (com- | products and services (4/98) | ||
| bines Cellomics' high- | |||
| content screening | |||
| systems with Zeiss' | |||
| ultra-high-throughput | |||
| screening system) | |||
| Centocor Inc. | Avakine (infliximab; | Schering-Plough Corp. | Schering-Plough gets exclusive marketing |
| chimeric monoclonal | (NYSE:SGP) | rights worldwide except in U.S., Japan and | |
| antibody to tumor | parts of the Far East; Centocor gets $20M | ||
| necrosis factor alpha) | up front and $30M in milestones tied to | ||
| for treating Crohn's | international approvals; companies will | ||
| disease (MAA sub- | divide profits on sales and share certain | ||
| mitted in Europe 3/98; | development expenses; Centocor retains | ||
| FDA advisory panel | U.S. marketing rights for all indications; | ||
| recommended approval | Centocor retains right to copromote (4/98) | ||
| 5/98) and rheumatoid | |||
| arthritis (Phase III | |||
| trial ongoing) | |||
| Cephalon Inc. | Modafinil (oral formu- | Nippon Shoji Kaisha | Nippon Shoji will develop and market |
| lation of synthetic com- | Ltd. (Japan) | product in Japan; Cephalon gets milestones | |
| pound that is thought | and royalties (6/98) | ||
| to affect alpha-adre- | |||
| nergic receptors in the | |||
| brain) for treating | |||
| narcolepsy | |||
| Chiron Corp. | Rabipur (cell culture- | Hoechst Marion Roussel | Formation of joint venture in India, to be |
| based rabies vaccine) | Inc. (subsidiary of | called Chiron Behring Vaccines Private | |
| and other vaccines | Hoechst AG; Germany) | Ltd. and owned 51% by Chiron and 49% | |
| by Hoechst Marion Roussel; joint venture | |||
| will manufacture Rabipur and other | |||
| vaccines; Hoechst Marion Roussel will | |||
| market products in India, Nepal, Sri Lanka | |||
| and Bangladesh; Chiron will market in | |||
| rest of world; Hoechst Marion Roussel will | |||
| also market certain other Chiron vaccines, | |||
| including for hepatitis A virus infection (5/98) | |||
| Chiroscience Group | Chirocaine (long-acting | Zeneca Group plc | Zeneca gets exclusive license to market |
| plc (U.K.) | local anesthetic that | (LSE:ZEN; U.K.) | product worldwide, except Japan; Chiro- |
| contains levobupiva- | science responsible for registering product | ||
| caine) for use in wide | in Europe and U.S.; Zeneca will take on | ||
| range of surgical | all further marketing responsibilities and | ||
| procedures | fund Phase IIIb/IV trial as well as register | ||
| product in remaining territories; Zeneca gets | |||
| exclusive rights to Chirocaine trademark; | |||
| Chiroscience retains right to manufacture | |||
| active ingredient; Chiroscience retains | |||
| rights in Japan and rights to other uses of | |||
| levobupivacaine; Chiroscience gets royal- | |||
| ties on Zeneca's sales; separately, Zeneca | |||
| bought 3.5M shares of Chiroscience at | |||
| $7.12 each for $25.1M total (3.17% equity | |||
| stake) (3/98) | |||
| Cortecs plc (U.K.) | Macritonin (oral form- | Glaxo Wellcome AEBE | Glaxo will distribute product in Greece; |
| ulation of salmon | (Greece; unit of Glaxo | Cortecs gets milestones and sales minima | |
| calcitonin) for treating | Wellcome plc; NYSE: | of $14M; Glaxo will participate in registra- | |
| postmenopausal | GLX; U.K.) | tion process in Greece (Cortecs submitted | |
| osteoporosis | marketing application in 10/97); Cortecs | ||
| will manufacture and supply product (5/98) | |||
| Cortecs Diagnostics | Helisal OneStep rapid | Becton Dickinson & Co. | Becton Dickinson will distribute products |
| Ltd. (subsidiary of | test (for detecting | (NYSE:BDX) | in U.S.; agreement allows for addition of |
| Cortecs plc; U.K.) | Helicobacter pylori | other territories; companies will collaborate | |
| infection) and Link2 | to develop other products using Cortecs' | ||
| infectious mononucleosis | one-step technology (6/98) | ||
| rapid test (point-of-care) | |||
| Helisal OneStep | Boehringer Mannheim | New distribution agreement that replaces | |
| (rapid point-of-care | GmbH (Germany) | former exclusive rights held by Boehringer | |
| assay for Helicobacter | with nonexclusive rights to distribute prod- | ||
| pylori infection) | uct outside Japan (6/98) | ||
| Cygnus Inc. | GlucoWatch (noninva- | Becton Dickinson & Co. | Termination of 2/96 marketing and distri- |
| sive, continuous glucose | (NYSE:BDX) | bution agreement, based on reevaluation | |
| monitoring device for | by both companies of long-range business | ||
| management of diabetes) | strategies and consideration of changes in | ||
| diabetes monitoring arena that have occur- | |||
| red since original agreement signed (3/98) | |||
| Cytogen Corp. | Quadramet (radio- | The DuPont Merck | Termination of 12/94 licensing agreement |
| pharmaceutical Sam- | Pharmaceutical Co. | for DuPont Merck to market product in | |
| arium 153 EDTMP for | (was joint venture, but | U.S.; in 5/98, parties accused each other of | |
| treating bone pain asso- | in 5/98 DuPont agreed | breach of agreement, but by 6/98 the agree- | |
| ciated with bone metas- | to pay $2.6B to buy out | ment had been terminated; DuPont Merck | |
| tases; FDA-approved | Merck's half interest) | has initiated efforts to find new marketing | |
| 3/97) | partner for Cytogen; DuPont Merck paid | ||
| Cytogen $3.8M and will manufacture prod- | |||
| uct over next 2 years; Cytogen will begin mar- | |||
| keting directly to cancer centers (5/98; 6/98) | |||
| CytRx Corp. | Flocor (purified pol- | Abbott Laboratories | Abbott will manufacture Flocor on commer- |
| oxamer 188; surfactant) | (NYSE:ABT) | cial scale; Abbott will sterile-fill Flocor for | |
| for improving blood | CytRx and will manage its part of the chem- | ||
| flow in ischemic tissue | istry, manufacturing and controls (CMC) | ||
| section of planned NDA filing (4/98) | |||
| Dendreon Corp.* | DACS 300 System | Fresenius Critical Care | Fresenius will market and distribute prod- |
| (facilitates preparation | International (unit of | uct worldwide (4/98) | |
| of CD34-positive cells | Fresenius AG; Germany) | ||
| from peripheral blood) | |||
| Draxis Health Inc. | Lilly's drug Permax | Eli Lilly Canada Inc. | Draxis renewed its 1994 agreement to |
| (Canada) | (pergolide mesylate, | (unit of Eli Lilly and Co.; | exclusively market drug in Canada; Lilly |
| a D1 and D2 dopamine | NYSE:LLY) | will manufacture product and supply it to | |
| receptor agonist) for | Draxis exclusively for marketing and distri- | ||
| treating Parkinson's | bution in Canada; terms for 10 years with auto- | ||
| disease | matic yearly renewals thereafter; Draxis will | ||
| make fixed payments to Lilly of $6M over 5 | |||
| years, plus additional variable payments (5/98) | |||
| Enzon Inc. | Oncaspar (native L- | Rhone-Poulenc Rorer | Expansion of 12/93 marketing agreement; |
| asparaginase modified | Inc. (subsidiary of Rhone- | Rhone-Poulenc Rorer will now market prod- | |
| with polyethylene gly- | Poulenc Group; France) | uct in Pacific Rim (as well as other terri- | |
| col) for treating acute | tories) (5/98) | ||
| lymphoblastic leukemia | |||
| Immunex Corp. | Nuvance (soluble | Hoechst Marion | Immunex acquired product rights outside |
| interleukin-4 [IL-4] | Roussel Inc. (subsid- | North America (it already held North | |
| receptor) plus 3 other | iary of Hoechst AG; | American rights to all 4 molecules from a | |
| soluble receptors (IL-1 | Germany) | 1990 agreement between the parties); | |
| receptor types 1 and 2 | Immunex will pay Hoechst Marion Roussel | ||
| and IL-7 receptor) | a 1-time fee of $10M as well as royalties on | ||
| product sales (4/98) | |||
| Immunex's generic | IVX BioScience Inc. | Companies will collaborate to market each | |
| paclitaxel (extracted | (formerly IVAX Corp.; | other's paclitaxel products in U.S.; IVX | |
| from all parts of | AMEX:IVX) | acquired Immunex's ANDA for paclitaxel | |
| cultivars of Pacific | (submitted 8/97) in exchange for unspeci- | ||
| yew trees) and IVX's | fied cash payment; IVX also will acquire | ||
| branded paclitaxel | Immunex's inventories of bulk product; | ||
| Paxene (extracted from | if FDA approves Immunex's ANDA, it | ||
| needles and limb stock | gets royalties on sales; Immunex will pro- | ||
| of ornamental yew | mote IVX's Paxene (if FDA-approved) and | ||
| trees), both for treat- | will earn fees on product sales; transaction | ||
| ing various cancers | subject to antitrust considerations (6/98) | ||
| The Liposome Co. | Astra's MVI-12 unit | Astra USA Inc. | 3-year agreement; The Liposome Co. will |
| Inc. | vial (injectable multi- | (subsidiary of Astra | manufacture Astra's product; Astra will |
| vitamin product used by | AB; Sweden) | supply bulk product and will market fin- | |
| severely ill hospitalized | ished product; financial terms ND (4/98) | ||
| patients in need of nutri- | |||
| tional supplements) | |||
| Abelcet (amphotericin B | Wyeth-Ayerst Inter- | Wyeth-Ayerst will market product in | |
| lipid complex) for treat- | national Inc. (division | Austria (already markets Abelcet in | |
| ing severe systemic | of American Home | France, Italy, Sweden, Finland, Norway, | |
| fungal infections | Products Corp.; | Denmark and Iceland) (4/98) | |
| NYSE:AHP) | |||
| Matritech Inc. | NMP22 test kit for | Organon Teknika | Marketing and distribution in Spain and |
| management of patients | Espanola SA (Spain; | Portugal (4/98) | |
| with bladder cancer | unit of Akzo Nobel | ||
| (enzyme immunoassay | NV; the Netherlands) | ||
| that measures cancer- | |||
| specific nuclear matrix | |||
| protein antigens in | |||
| urine; FDA-approved | |||
| 7/96) | |||
| Molecular | Ultrasound contrast | Chugai Pharma- | Chugai gets exclusive license to market |
| Biosystems Inc. | imaging agents FS069 | ceuticals Ltd. (Japan) | products in Japan, Taiwan and South Korea; |
| (2nd-generation cardiac | Molecular Biosystems gets $14M up-front | ||
| imaging agent) and | license fee and $20M in milestones; Chugai | ||
| Oralex (oral imaging | will buy undisclosed equity stake in Molec- | ||
| agent for upper gastro- | ular Biosystems and pay royalties on prod- | ||
| intestinal tract) | uct sales (4/98) | ||
| Neoprobe Corp. | Gamma-guided surgery | Ethicon Endo-Surgery | Agreement has initial term of 1 year; |
| products (portable radio- | Inc. (a Johnson & John- | Ethicon will promote and sell products as | |
| isotope detector and | son company; NYSE: | well as train physicians in use of device; | |
| 14 mm and 19 mm | JNJ) | its initial territory is U.S., but expansion to | |
| reusable probes for | Europe, Japan and Australia is planned | ||
| gamma-guided lympha- | (4/98) | ||
| tic mapping and min- | |||
| imally invasive sur- | |||
| gery for cancer) | |||
| Neose Technologies | Use of Neose's multi- | Bristol-Myers Squibb | Neose will manufacture complex carbo- |
| Inc. | transferase reaction | Co. (NYSE:BMY) | hydrates for 2 oncology vaccines being |
| technology to produce | developed by Bristol-Myers; further details | ||
| complex carbohydrates | ND (6/98) | ||
| in large quantities | |||
| Neurex Corp. | Corlopam (dopamine | Crystaal Corp. (subsid- | Crystaal will obtain regulatory approval for |
| receptor agonist that | iary of Biovail Corp.; | drug and market it in Canada (4/98) | |
| causes dilation of | TSE:BVF; Canada) | ||
| blood vessels) for | |||
| treating short-term | |||
| hypertension (FDA- | |||
| approved 9/97) | |||
| Phyton Inc.* | Use of Phyton's plant | Bristol-Myers Squibb | Companies have been collaborating on |
| cell fermentation tech- | Co. (NYSE:BMY) | commercial plant cell fermentation technol- | |
| nology for commercial- | ogy since 1993; Phyton granted Bristol- | ||
| scale manufacturing of | Myers an exclusive license in 1995; now | ||
| paclitaxel (active ingre- | the companies intend to develop manufac- | ||
| dient in Bristol-Myer's | turing process for paclitaxel; Phyton gets | ||
| FDA-approved anti- | funding, milestones and royalties (6/98) | ||
| cancer product Taxol) | |||
| Qiagen GmbH (sub- | Organon's NASBA | Organon Teknika | Qiagen gets nonexclusive worldwide |
| sidiary of Qiagen NV; | technology (nucleic | (Belgium; unit of Akzo | license to develop, manufacture and market |
| the Netherlands) | acid sequence-based | Nobel NV; the Nether- | NASBA reagent kits to research market |
| amplification) for | lands) | (3/98) | |
| research purposes | |||
| SciClone | Zadaxin (thymosin alpha | Sclavo SpA (Italy) | SciClone acquired marketing approval in |
| Pharmaceuticals | 1; synthetic version of | Italy for Zadaxin as vaccine adjuvant and | |
| Inc. | naturally occurring hor- | marketing application in Italy for non- | |
| mone thymosin) for | small cell lung cancer from Sclavo (to | ||
| use as vaccine adjuvant | which it had sublicensed those rights in | ||
| and for treating non- | 1997); SciClone also acquired all of | ||
| small cell lung cancer | Sclavo's development and marketing rights | ||
| in Spain and Portugal; SciClone paid in the | |||
| aggregate $1.84M for these rights ($0.3M | |||
| cash; 0.38M shares SciClone stock for | |||
| $1.54M and 2-year warrants for 0.38M | |||
| shares SciClone stock) (4/98) | |||
| Scios Inc. | Natrecor (genetically | Bayer AG (Germany) | Bayer gets exclusive worldwide rights to |
| engineered version of | market product; Scios will supply drug to | ||
| naturally occurring | Bayer; Scios will manage Phase IIIb clin- | ||
| cardiac hormone human | ical trials; Bayer will manage further | ||
| B-type natriuretic | worldwide development and commercial- | ||
| peptide) for short-term | ization; Scios has option to participate in | ||
| treatment of congestive | further drug development; Scios gets $20M | ||
| heart failure (NDA sub- | up-front cash payment and cash milestones | ||
| mitted 4/98) | up to $40M total on regulatory approvals | ||
| in U.S., Europe and Japan; Scios also gets | |||
| payments for supplying drug; Scios has | |||
| option to copromote in U.S. after 3 years | |||
| (5/98) | |||
| Janssen's antipsychotic | Janssen Pharmaceutica | Scios will copromote drug; further details | |
| drug Risperdal (risperi- | NV (Belgium; subsid- | ND (5/98) | |
| done) | iary of Johnson & | ||
| Johnson; NYSE:JNJ) | |||
| Wyeth-Ayerst's anti- | Wyeth-Ayerst Labor- | Termination of 4/96 agreement for Scios to | |
| depressant drug Effexor | atories (division of | copromote product in U.S.; agreement | |
| (venlafaxine HCl; | American Home | terminated by mutual consent (5/98) | |
| serotonin and nor- | Products Corp.; | ||
| epinephrin reuptake | NYSE:AHP) | ||
| inhibitor) | |||
| Sequus | Amphotec (a.k.a. | Faulding Pharma- | Exclusive 5-year agreement for Faulding to |
| Pharmaceuticals | Amphocil; lipid-based | ceuticals (division of | market, sell and distribute product in New |
| Inc. | colloidal dispersion of | F.H. Faulding & Co. | Zealand, Australia and Southeast Asia |
| amphotericin B) for | Ltd.; Australia) | (5/98) | |
| treating systemic fungal | |||
| infections | |||
| Unigene | Fortical Injection | Tzamal Pharma Ltd. | Tzamal gets exclusive license to distribute |
| Laboratories Inc. | (recombinant | (Israel) | product in Israel and surrounding area; |
| salmon calcitonin) | Unigene gets revenues from sales of fin- | ||
| for treating osteo- | ished product to Tzamal; Tzamal will reg- | ||
| porosis | ister product and distribute it to managed | ||
| care and private markets (3/98) | |||
| Vanguard Medica | Frovatriptan (sero- | SmithKline Beecham | SmithKline Beecham terminated its mar- |
| Ltd. (U.K.) | tonin 5-hydroxy- | plc (NYSE:SBH; U.K.) | keting agreement on the drug; all rights |
| tryptamine [5HT] | return to Vanguard; SmithKline gets roy- | ||
| antagonist) for treat- | alties on sales (5/98) | ||
| ing migraine | |||
| Viragen Inc. | Human white blood | Southern Health | Southern Health has option to acquire |
| cell-derived natural | SDN.BHD (Malaysia and | exclusive private-label license to | |
| interferon | Australia) | Viragen's production process for interferon; | |
| Viragen gets $0.2M option fee (option | |||
| expires 9/30/98); if exercised, Viragen gets | |||
| up-front license fee of $20M and a continu- | |||
| ing 12% royalty; Southern required to | |||
| begin building at least 1 production | |||
| facility in its territories (Australia, New | |||
| Zealand and several Asian countries, but | |||
| excluding China and Japan) within 1st 2 years; | |||
| Southern responsible for funding and con- | |||
| ducting clinical trials in its territories (4/98) | |||
| NOTES: | |||
| # This chart does not include any marketing and/or distribution agreements that involve agricultural product development. The information in the chart covers the time period between 3/25/98 and 6/15/98. | |||
| ASX = Australia Stock Exchange; ND = Not disclosed, reported and/or available; LSE = London Stock Exchange; TSE = Toronto Stock Exchange | |||
| * Private companies are indicated with an asterisk. | |||
| ** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 16-17. | |||